Search Videos and More
News
Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute Leukemia
A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
News
Dana-Farber Research Publication 03.15.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Studies of Novel Therapeutic Approaches Highlighted During Colorectal Cancer Awareness Month at Dana-Farber
Colorectal cancer is the 3rd most common cancer among men and women of all ages in the US and is on track to be the leading cause of cancer death in adults under 50 by 2030.
News
Therapy for Small, HER2-positive Breast Tumors Continues to Be Highly Effective After 10 Years, Study Finds
Follow-up results of a clinical trial that defined the standard treatment for patients with small, HER2-positive breast cancer that hasn't spread to the lymph nodes reinforce the long-term effectiveness of the therapy.
Podcast
Season 2, Episode 2: Thalidomide and its Second Act in Multiple Myeloma
Momentum isn't always one way. And it's not always constant. Sometimes it shoves you sideways, sometimes it stops you in your tracks. And sometimes only sometimes, it drives you to write one of the most astonishing second acts in all of medicine. That's the story of thalidomide.
News
Study Suggests Possible Way to ‘Smac’ Cancer
In a new study, researchers at Dana-Farber Cancer Institute used cryo-electron microscopy to reveal for the first time how one IAP, a protein called BIRC6, operates at a molecular level to inhibit programmed cell death.
Podcast
Season 2, Episode 1: BCL-2 Inhibitors: Driving Cells to Destruction
The story begins decades ago with a man named Stanley Korsmeyer, who led the molecular oncology program at Dana-Farber from 1998 until his death in 2005. He discovered that B cell cancers like CLL over-produced a protein called Bcl-2, and interfered with apoptosis, or programmed cell death. But how that went from an interesting discovery to a game-
Video
Smoldering Multiple Myeloma - A Unique New Approach
When Deidre was diagnosed with a precursor condition to multiple myeloma she enrolled in a brand-new clinical trial being conducted at Dana-Farber Cancer Institute. Deidre and her doctor, Dana-Farber's Irene Ghobrial, MD, explain more in this video.
News
Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer
Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic HR+, HER2- breast cancer.
News
Dana-Farber Researcher Awarded Victoria Mock New Investigator Award
Rachel Pozzar, PhD, RN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute and an instructor in medicine at Harvard Medical School, has been awarded the 2023 Oncology Nursing Society’s (ONS) Victoria Mock New Investigator Award.
News
Dana-Farber Research Publication 02.01.2023
This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.
News
Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia
On Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).